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Background  Today	  GBS	  vaccines	  for	  prevention	  of	  severe	  neonatal	  disease	  through	  transplacental	  delivery	  
of	  antibodies	  directly	  from	  immunized	  mothers	  are	  in	  advanced	  stage	  of	  development.	  	  For	  the	  introduction	  of	  
any	  GBS	   vaccine	   there	   are	   urgent	   needs	   for	   pre	   and	   post	   vaccine	   enhanced	   surveillance	   studies	   of	   strains	  
isolated	   from	   both	   neonatal	   diseases	   and	   vagino-­‐rectal	   colonization	   of	   pregnant	   women.	   In	   Belgium,	  
surveillance	   of	   invasive	   isolates	   is	   regularly	   done	   by	   the	   NRC.	   	  We	   report	   in	   this	   study	   a	   surveillance	   of	  
colonizing	  isolates	  of	  GBS.	  
Methods  In	  2012,	  382	  GBS	  isolates	  were	  obtained	  from	  a	  Belgian	  surveillance	  for	  vagino-­‐rectal	  colonization	  
among	  pregnant	  women	   (max.	   5	   isolates/lab).	   	  Capsular	   types	  were	   determined	   by	   agglutination	   (Strep-­‐B-­‐
latex,	  SSI,	  Denmark)	  and	  genotyping	  (PCR),	  and	  MICs	  by	  using	  a	  microdilution	  method	  (Sensititre)	  and	  Etest®	  
(EUCAST	   interpretive	   criteria).	   Furthermore,	   for	   the	   erythromycin	   (E)	   resistant	   (R)	   isolates,	   the	   inducible	  
(iMLS),	  constitutive	  (cMLS)	  and	  M	  phenotypes	  were	  assessed	  by	  a	  double-­‐disk	  diﬀusion	  test.	  	  
Results	  	  Serotype	  III	  was	  the	  more	  common	  (29.3%)	  followed	  by	  V,	  Ia,	  II,	  Ib,	  IV,	  VI,	  VII	  and	  IX	  (19.9%, 17.8%, 
17.8%, 8.1%, 5.2%, 0.3%, 0.3%, 0.3%)	   and	   1%	   were	   non	   typable.	   	   All	   isolates	   were	   susceptible	   to	  
penicillin	  ;	  29%	  were	  R	  to	  E	  with	  a	  higher	  rate	  among	  serotypes	  IV	  and	  V	  (p<0.05).	   	  Among	  these	  E-­‐R	  isolates,	  
92%	  exhibited	  the	  MLS	  phenotype	  (R	  to	  E	  and	  CC):	  53%	  were	  cMLS	  with	  E MIC50>256 mg/L and 39% iMLS	  
with	  E MIC50/MIC90 2/>8 mg/L.	  The	  M	  phenotype	   (R	  to	  E	  and	  S	  to	  C)	  was	  expressed	  by	  8%	  of	  E-­‐R	   isolates	  
with	  E	  MIC50/MIC90 2/4 mg/L. !
Conclusions  Compared	  with	  Belgian	  data	  relating	  to	  neonatal	  invasive	  strains	  (NRC	  reports)	  1)	  Serotype	  V	  
and	   II	   are	   more	   frequent	   and	   III	   less	   frequent	   among	   colonizing	   isolates	   2)	   Prevalence	   of	   E-­‐R	   is	   similar	   in	  
percentage	  and	  phenotypes	  with	  the	  MLS	  R	  phenotype	  as	  major	  mechanism.	  Extended	  surveillance	  of	  both	  





From	  the	  1990s	  to	  the	  present,	  where	  guidelines	  for	  prevention	  of	  perinatal	  GBS	  disease	  have	  
been	   widely	   implemented,	   the	   incidence	   of	   neonatal	   early	   onset	   disease	   (EOD)	   has	  
dramatically	   decreased	   to	   <0.5	   cases	   per	   1,000	   live	   births	   but	   has	   not	   been	   eradicated	   and	  
continues	   to	  be	   an	   important	   cause	  of	   neonatal	   sepsis	   and	  meningitis.	   	  There	   are	   numerous	  
prevention	   strategies	  at	   this	   time	  but	  none	  are	  100%	  eﬀective	   in	   the	  eradication	  of	  neonatal	  
GBS	  EOD	  and	  there	  are	  no	  preventive	  strategies	  for	  late	  onset	  disease	  (LOD).	  	  Development	  of	  
a	  group	  B	  streptococcal	  vaccine	   is	   the	  most	  promising	  approach	   for	   the	  prevention	  of	   severe	  
GBS	  neonatal	   disease	   through	   transplacental	   delivery	  of	   antibodies	  directly	   from	   immunized	  
mothers.	  	  Pre	  and	  post	  vaccine	  enhanced	  surveillance	  studies	  of	  GBS	  strains	  isolated	  from	  both	  
neonatal	  diseases	  and	  vagino-­‐rectal	  colonization	  of	  pregnant	  women	  are	  of	  critical	  importance.	  
For	  the	  treatment	  of	  GBS	  infections	  or	  for	  intrapartum	  chemoprophylaxis	  penicillin	  is	  the	  ﬁrst	  
line	   antibiotic	   and	   for	   penicillin	   allergic	   patients	   clindamycin	   is	   an	   eﬀective	   recommended	  
alternative.	   	   Empiric	   therapy	   of	   severe	   GBS	   infections,	   initiated	   before	   availability	   of	  
susceptibility	   results,	   and	   intrapartum	   chemoprophylaxis	   to	   prevent	  GBS	   EOD	   are	   based	   on	  
accurate	   susceptibility	   surveillance	   data.	   	   But	   globally,	   resistance	   to	   macrolides	   and	  
lincosamides	  has	  increased	  among	  GBS	  isolates	  over	  the	  last	  two	  decades:	  from	  less	  than	  5%	  to	  
common	   resistance	   of	   20%	   to	   30%.	   Diﬀerent	   known	   mechanisms	   account	   for	   acquired	  
resistance	  to	  macrolides	  in	  streptococci.	  The	  most	  prevalent	  of	  these	  is	  target	  site	  modiﬁcation	  
by	   23S	   rRNA	   methylases.	   These	   enzymes	   confer	   resistance	   to	   macrolides	   and	   inducible	   or	  
constitutive	   resistance	   to	   lincosamides	   and	   streptogramin	   B,	   so-­‐called	   MLSB	   phenotype.	  
Another	  mechanism,	  involving	  active	  drug	  eﬄux,	  the	  Mef	  pump	  aﬀects	  14-­‐	  and	  15-­‐	  membered	  
ring	  macrolides	   but	   not	   16-­‐membered	  macrolides,	   neither	   lincosamides	   nor	   streptogramin	  B	  
(M	  phenotype).	  Apart	  from	  these	  worrying	  resistances,	  another	  phenotype	  involving	  low-­‐level	  
of	   clindamycin	   resistance	   (with	   erythromycin	   remaining	   susceptible)	   in	   GBS	   isolates	   has	  
recently	  been	  reported	  in	  many	  countries:	  the	  L	  phenotype.	  	  
In	   Belgium,	   the	  NRC	   routinely	   performs	   surveillance	   of	   invasive	  GBS	   isolates,	   but	   for	   strains	  
isolated	   from	  colonized	  pregnant	  women,	   epidemiological	   surveys	  on	   strains	   isolated	   in	   labs	  
from	  a	  national	  network	  or	  limited	  to	  regional	  area	  are	  organized	  periodically.	  	  We	  report	  in	  this	  
study	   a	   surveillance	   of	   colonizing	   isolates	   of	   GBS:	   distribution	   of	   capsular	   serotypes	   and	  
antimicrobial	  susceptibility	  proﬁle.	  
!
OBJECTIVES 
GBS	   vaccination	   era	   approaching,	   this	   study	   focusing	   on	   the	   distribution	   of	  
circulating	   capsular	   serotypes	   among	  GBS	   isolated	   from	   colonized	   pregnant	  
women	   and	   on	   their	   antimicrobial	   susceptibility	   patterns,	   was	   designed	   to	  
determine	  a	  Belgian	  reference	  baseline.	  	  It	  should	  help	  to	  understand	  potential	  
epidemiological	   changes	   among	  GBS	   isolated	   from	   severe	   neonatal	   diseases	  
and	  from	  colonized	  pregnant	  women	  following	  GBS	  vaccine	  introduction.	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METHODS 
Clinical	  isolates	  from	  colonized	  pregnant	  women	  
In	  2012,	  all	  Belgian	  laboratories	  were	  invited	  to	  send	  to	  the	  National	  Reference	  Centre	  (NRC)	  
for	  GBS	   ﬁve	   consecutive	   S.agalactiae	   isolated	   from	   vagino-­‐rectal	   specimens	   	   for	   further	  
characterization	  and	  epidemiological	  purposes.	  A	  total	  of	  382	  isolates	  of	  GBS	  were	  included	  
in	  this	  study.	  
Upon	  reception,	  strains	  were	  subcultured,	  identiﬁcation	  was	  conﬁrmed	  and	  they	  were	  stored	  
in	  skimmed	  milk	  at	  	  -­‐80°C	  before	  further	  testing.	  
	  
Control	  strains	  
A	   set	   of	   GBS	   strains	   with	   characterized	   phenotypes	   and	   genetotypes,	   belonging	   to	   the	  
collection	  of	  the	  NRC	  for	  GBS	  were	  used	  as	  reference	  strains	  for	  quality	  control.	  
•  Ten	  reference	  GBS	  strains,	  one	  for	  each	  capsular	  types	  Ia,	  Ib-­‐IX.	  
•  Four	  GBS	  strains	  representing	  the	  diﬀerent	  macrolide-­‐lincosamide	  resistant	  phenotypes.	  
Determination	  of	  capsular	  types	  
Serotyping	  
All	  strains	  were	  submitted	  to	  serotyping	  by	  agglutination	  with	  Strep-­‐B-­‐Latex	  (SSI,	  Denmark)	  
using	  a	  micro-­‐method	  according	  to	  Afschar	  et	  al	  (2011).	  	  	  
Genotyping	  
All	  strains	  that	  were	  non-­‐typable	  	  or	  had	  a	  weak	  positive	  reaction	  by	  the	  agglutination	  method	  
were	   additionally	   tested	   using	   multiplex	   PCR	   based	   on	   the	   detection	   of	   GBS	   capsular	  
polysaccharide	  genes	  according	  to	  Poyart	  (2007)	  and	  Kong	  (2008).	  	  
Determination	  of	  MICs	  
All	   isolates	   were	   submitted	   to	   determination	   of	   MICs	   by	   the	   microdilution	   method	   using	  
Sensititre	  speciﬁc	  panels,	  customized	  for	  the	  Belgian	  NRC	  for	  GBS.	  
Interpretation	  of	  MICs	   according	   to	   “Breakpoints	   tables	   for	   interpretation	  of	  MICs	   and	   zone	  
diameters”	  edited	  by	  EUCAST	  (V2.0,	  2012).	  
Determination	  of	  macrolide	  resistance	  phenotypes	  	  
§  All	   strains	   showing	   resistance	   to	   erythromycin	   and/or	   clindamycin	   were	   submitted	   to	   a	  
Dtest:	  
§  Erythromycin	  (15	  mg)	  and	  clindamycin	  (2	  mg)	  double-­‐disk	  diﬀusion	  assay.	  
§  Disks	  placed	  18	  mm	  apart	  (edge	  to	  edge)	  on	  inoculated	  Mueller	  Hinton	  agar	  +	  5%	  sheep	  
blood	  ;	  18-­‐24	  h	  incubation	  at	  35°C.	  	  
§  Interpretation:	  
•  MLSB	  phenotype	  
•  Inducible	   resistance	   (iMLS):	   resistance	   to	   erythromycin	   and	   blunting	   of	   the	  
clindamycin	  zone	  of	  inhibition	  proximal	  to	  the	  erythromycin	  disk	  or	  “D	  shaped	  zone”	  
•  Constitutive	  resistance	  (cMLS):	  resistance	  to	  both	  erythromycin	  and	  clindamycin	  
•  M	  phenotype:	   resistance	   to	   erythromycin	   and	   susceptibility	   to	   clindamycin	  with	  no	  
blunting	  of	  the	  clindamycin	  zone	  of	  inhibition.	  
•  L	  phenotype:	  susceptibility	  	  to	  erythromycin	  and	  resistance	  to	  clindamycin.	  
!
RESULTS AND DISCUSSION 
Distribution	  (%)	  of	  capsular	  types	  of	  GBS	   	   	   	   	   	   	   	  	  
Figure 1: Distribution of types among 382 clinical isolates of GBS colonizing pregnant  
women (2012) compared to distribution of 111 (2011) and 322 (2002) GBS colonizing  









Antimicrobial	  susceptibility	  proﬁle	  
  Table 1: Antimicrobial susceptibility profile of 382 clinical isolates of GBS colonizing  

























   Within the first period, isolates from adults and serotype V isolates were  
significantly more resistant to erythromycin (p<0.01 and p< 0.001). 
   More recently, neonatal isolates have demonstrated the same level of resistance  
to erythromycin as adult isolates.  And, serotypes IV, V, VI and VII are more  
 resistant to erythromycin (p<0.001). 





























0.03 - 0.25 
<0.06 - >256 
<0.06 - >256 
<0.06 - 8 
<0.12 - 4 
<0.12 - 4 
<0.12 - 64 
Macrolide	  resistance	  phenotypes	  
 
Table 2: Distribution of macrolide resistance phenotypes  among 111 isolates of GBS 










   
Phenotypes  % Ery MIC50 / MIC90              
(mg/L) 




128 /  >128 
4  /  128 
M 8.1   2  /  4 
L 1.8 0.12 / 0.12 
!
CONCLUSION 
 	  Some	  evolution	  was	  showed	  in	  the	  distribution	  of	  capsular	  types	  of	  GBS	  :	  increase	  of	  types	  III	  and	  V.	  	  
 	  All	  tested	  strains	  of	  GBS	  isolated	  from	  pregnant	  women	  were	  susceptible	  to	  penicillin,	  the	  ﬁrst	  line	  agent	  recommended	  for	  intrapartum	  prophylaxis	  (IAP)	  and	  therapy.	  	  
 	  On	  the	  other	  hand,	  prevalence	  of	  resistance	  to	  antibiotics	  commonly	  used	  for	  prophylaxis	  of	  GBS	  infection	  in	  penicillin	  allergic	  patients	  was	  found.	  	  GBS	  resistant	  to	  clindamycin	  and	  erythromycin	  was	  common.	  
 High	  rates	  of	  erythromycin	  resistance	  are	  particularly	  associated	  with	  serotypes	  IV	  and	  V.	  	  
 As	  previously	  reported	  in	  Belgium	  or	  in	  other	  European	  countries,	  most	  of	  erythromycin	  resistant	  isolates	  showed	  a	  MLS	  phenotype.	  	  
 Clindamycin	  resistance	  without	  concurrent	  erythromycin	  resistance	  can	  be	  observed	  rarely.	  	  
  These	  ﬁndings	  are	  consistent	  with	  previous	  Belgian	  reports	  and	  support	  2003	  Belgian	  guidelines	  /	  CDC	  2010	  guidelines	  requiring	  susceptibility	  testing	  of	  isolates	  from	  IAP	  candidates	  with	  penicillin	  allergy	  and	  
the	  need	  for	  regular	  epidemiological	  surveys,	  especially	  after	  introduction	  of	  GBS	  vaccines.	  
The	   observed	   rates	   of	   resistance	   to	   erythromycin	   showed	   relationships	  
between	   resistance	   to	   erythromycin	   and	   capsular	   type.	   Erythromycin	  
resistant	   strains	   were	   mostly	   types	   IV	   and	  V	   (	   (P<0.001).	   	   Erythromycin	  
resistance	  was	  2.8	  to	  4.5	  times	  	  more	  likely	  to	  occur	  in	  type	  IV	  and	  V	  isolates	  
(55	  and	  58%)	  than	  in	  other	  serotypes.	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The	   distribution	   observed	   in	   2002	   is	   based	   on	   serotyping	   alone	   while	  
genotyping	   was	   added	   for	   strains	   collected	   in	   2011	   and	   2012.	   	   Since	  
2002,	  the	  distribution	  has	  evolved	  with	  a	  decrease	  of	  the	   	  ratio	  of	  types	  
Ia	  and	  Ib	  	  in	  favor	  of	  types	  III	  and	  V	  (P<0.001).	  
All	  strains	  were	  susceptible	  to	  penicillin	  but	  the	  range	  of	  determined	  MICs	  
extended	   up	   to	   0.25	   mg/L.	   Penicillin	   susceptibility	   requires	   speciﬁc	  
attention	   and	   follow	  up	   to	   look	   for	   emergence	   of	   strains	  with	   reduced	  
susceptibility.	  	  
For	   erythromycin/clindamycin,	   resistance	  was	   common	  and	   the	  observed	  
rates	  of	   resistance,	  28.6%	  and	  26.7	  %,	  are	  consistent	  with	  Belgian	  GBS	  
data	  even	  if	  slightly	   lower	  than	  the	  33%	  and	  31.3	  %	  reported	  for	  clinical	  
GBS	   strains	   isolated	   from	   invasive	   diseases	   (Belgian	   Edition	   of	   the	  
Sanford	  Guide	  2012).	  
Resistance	  to	  ﬂuoroquinolones	  was	  identiﬁed	  among	  2-­‐3%	  of	  GBS	  isolated	  
from	   colonized	   pregnant	   women	   which	   is	   much	   lower	   than	   the	  Asian	  
rates	  as	  the	  38%	  reported	  in	  China	  (Wang	  et	  al,	  2013).	  
The	  high	   resistance	   to	   tetracycline	   is	   stable	   since	   several	   decades	   as	   it	   is	  
globally.	  
	  
For	   erythromycin/clindamycin,	   the	  observed	  distribution	  of	   the	  diﬀerent	  
phenotypes	   of	   resistance	   among	  GBS	   isolated	   from	   colonized	   pregnant	  
women	   is	   consistent	   with	   Belgian	   GBS	   data	   reported	   for	   clinical	   GBS	  
strains	   isolated	   from	   invasive	   diseases	   (Belgian	   edition	   of	   the	   Sanford	  
Guide	   2012).	   The	   main	   mechanism	   is	   a	   target	   site	   modiﬁcation,	  
constitutive	  or	  inducible,	  among	  90%	  of	  the	  resistant	  strains.	  	  
The	  L	  phenotype,	  described	  initially	  in	  South	  America,	  Australia	  and	  New	  
Zealand,	  has	  been	  identiﬁed	  among	  1.8%	  of	  isolates	  of	  this	  collection	  and	  
has	   also	   been	   observed	   since	   2010	   in	   very	   few	   strains	   isolated	   from	  
bacteriuria	  (CNR	  unpublished	  data).	  
	  
Macrolide	  resistance	  among	  diﬀerent	  capsular	  types	  
 
Figure 2: Rate of resistance to erythromycin among the 6 main capsular types of 364 
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